Filing Flows

Filing Flows › Acadia Pharmaceuticals (ACAD) › Next earnings date

Acadia Pharmaceuticals (ACAD) earnings: beat the estimate

Acadia Pharmaceuticals (ACAD) reported on Nov 4, 2026 and beat the EPS estimate: $0.31 against $0.18 (+69.9%). Revenue was $342M for Q3 2026, +23% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+69.9% vs estimate
Beat rate60%

The last report

Acadia Pharmaceuticals reported revenue of $342M for the third quarter 2026 (+23% Y/Y), net earnings $53.5M: Nuplazid $202M, Daybue $140M. How it makes money → · Every quarter →

Acadia Pharmaceuticals: EPS against the estimate, last 5 reportsAcadia Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.15$0.42Nov 25$0.14$0.14Feb 26$0.08$0.02May 26$0.04$0.18Aug 26$0.18$0.31Nov 26
Latest (Nov 26): Estimate $0.18, Reported $0.31.

Acadia Pharmaceuticals' latest quarter

Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Acadia Pharmaceuticals beat earnings?

Acadia Pharmaceuticals (ACAD) reported on Nov 4, 2026 and beat the EPS estimate: $0.31 against $0.18 (+69.9%).

When does ACAD report earnings?

The next date is not set yet.

Does Acadia Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.